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ABSTRACT:  
A major challenge associated with biochemical and cellular analysis of pseudokinases is a lack of 
target-validated small molecule compounds with which to probe function. Tribbles 2 (TRIB2) is a 
cancer-associated pseudokinase with a diverse interactome, including the canonical AKT signaling 
module. There is substantial evidence that human TRIB2 promotes survival and drug-resistance in 
solid tumors and blood cancers and therefore is of interest as a therapeutic target. The unusual TRIB2 
pseudokinase domain contains a unique cysteine-rich C-helix and interacts with a conserved peptide 
motif in its own C-terminal tail, which also supports its interaction with E3 ubiquitin ligases. Here, we 
found that TRIB2 is a target of previously described small molecule protein kinase inhibitors, which 
were originally designed to inhibit the canonical kinase domains of epidermal growth factor receptor 
(EGFR) tyrosine kinase family members. Using a thermal-shift assay (TSA), we discovered TRIB2-
binding compounds within the Published Kinase Inhibitor Set (PKIS), and used a drug repurposing 
approach to classify compounds that either stabilized or destabilized TRIB2 in vitro. TRIB2 
destabilizing agents, including the covalent drug afatinib, led to rapid TRIB2 degradation in human 
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AML cancer cells, eliciting tractable effects on signaling and survival. Our data reveal new drug leads 
for the development of TRIB2-degrading compounds, which will also be invaluable for unravelling 
the cellular mechanisms of TRIB2-based signaling. Our study highlights that small molecule-induced 
protein downregulation through drug “off-targets” might be relevant for other inhibitors that 
serendipitously target pseudokinases. 
INTRODUCTION:  
The human protein kinome encodes ~60 protein pseudokinases, which lack at least one conventional 
catalytic residue, but often control rate-limiting signaling outputs within cellular networks [1]. Like 
canonical kinases, pseudokinases drive conformation-dependent signaling associated with both 
physiology and disease [2, 3]. The human ‘pseudokinome’ includes cancer-associated signaling 
proteins such as human epidermal growth factor receptor 3 (HER3), Janus kinase 2 (JAK2; JH2 
domain) and Tribbles 2 (TRIB2), which have received much less attention than their conventional, 
catalytically-active counterparts even though pseudokinase domains represent rational targets for drug 
discovery [4]. Discovering or repurposing biologically and/or clinically-active compounds that target 
atypical-conformations of canonical kinases or pseudokinases, is an area of active research [2, 3, 5-9]. 
Moreover, the burgeoning pseudokinase field is strongly placed to benefit from the decades of 
research undertaken on canonical protein kinases, which has seen the approval of over 40 kinase 
inhibitors for human cancer and inflammatory diseases [10, 11].  This includes understanding how 
ATP-competitive, allosteric, or covalent inhibitors might influence pseudokinase-based signaling 
mechanisms that are relevant to health and disease [3, 12]. 
The three human TRIB pseudokinases (TRIB1, TRIB2, and TRIB3) and the related pseudokinase 
STK40 (serine/threonine kinase 40, also known as SgK495) are homologues of the Drosophila 
melanogaster pseudokinase termed Tribbles, which controls ovarian border cell and neuronal stem 
cell physiology in flies [13, 14] These proteins contain a catalytically-impaired pseudokinase domain. 
Adaptions in the pseudokinase fold, including a highly unusual aC-helix, are thought to support a 
competitive regulatory interaction in cis with a unique C-terminal tail DQLVP motif [15-17]. Through 
a still obscure mechanism, TRIB and STK40 function as adaptor proteins that recruit ubiquitin E3 
ligases, such as constitutive photomorphogenesis protein 1 homolog (COP1), through interaction with 
the conserved C-tail peptide	[15, 17], which is also required for signaling and cellular transformation 
[18]. Mechanistically, Tribbles proteins’ signaling outputs are controlled through the ubiquitylation 
and subsequent proteasomal destruction of Tribbles ‘pseudosubstrates”; in vertebrates, these include 
the transcription factor C/EBPa, the cell cycle-associated phosphatase CDC25C, and the enzyme 
acetyl CoA carboxylase [19-21]. 
A longstanding goal in cancer research is drug-induced degradation of oncogenic proteins. Progress 
towards this objective has been transformed by the synthesis of proteolysis-targeting chimeras 
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(PROTACs), which induce proteasome-dependent degradation of their targets. Multifunctional small 
molecule PROTACS often possess protein-binding regions derived from kinase inhibitors [22, 23], 
and multiple classes of non-PROTAC kinase inhibitor also induce kinase target degradation, although 
typically at higher (micromolar) concentrations than those required for enzymatic inhibition [7]. 
Recent reports also disclose classes of covalent compounds that bind and disable cysteine (Cys)-
containing small G-proteins such as mutant human RAS, permitting covalent inactivation of this 
previously ‘undruggable’ oncoprotein [24, 25]. Cys residues are widespread and highly conserved in 
kinases [26] and the conservation of Cys residues both inside and outside the catalytic domain 
provides kinome-wide opportunities for exploitation using chemical biology [27]. In this context, 
covalent targeting methodologies involving compound-accessible Cys residues in kinases [8, 28-31] 
and pseudokinases [3], have attracted significant attention for small molecule design, due to the 
potential for gains in target specificity and durability of responses, combined with tractability in 
experimental systems.  
Tribbles pseudokinases are implicated in many physiological signaling pathways, often in the context 
of protein stability, but also through regulation of key modules, such as the canonical AKT pathway 
[32]. TRIB2 is also implicated in the aetiology of human cancers, including leukemias, melanoma, 
and lung and liver cancers [33]. In particular, TRIB2 is a potential drug target in subsets of acute 
myeloid and lymphoid leukemia (AML and ALL), which are in urgent need of targeted therapeutics 
to help treat untargeted or drug-resistant patient populations [34]. TRIB2 protein abundance has also 
been linked to drug-resistance mechanisms, where an ability to modulate the pro-survival AKT 
signaling module underlies a central regulatory role in cell proliferation, differentiation, metabolism, 
and apoptosis [32, 35-39].  
Here, we found that the low-affinity ATP-binding site in TRIB2 [40] was druggable with small 
molecules previously described as ATP-competitive pan-EGFR family kinase inhibitors. Biochemical 
analysis confirmed the existence of distinct compound-induced TRIB2 conformations and a 
compound screen identified known EGFR family inhibitors that stabilize or destabilize TRIB2 in 
vitro. TRIB2-binding compounds included the clinically used breast cancer therapeutic lapatinib 
(marketed as Tykerb) [41] and the FDA-approved irreversible electrophilic covalent inhibitors 
afatinib (Giotrif) [42, 43] and neratinib (Nerlynx) [44, 45]. In the case of the latter two destabilizing 
agents, binding led to uncoupling of the pseudokinase domain from its own C-terminal tail. 
Consistently, afatinib exposure led to rapid TRIB2 degradation in cells, driven by an interaction with 
the Cys-rich pseudokinase domain, which interfered with AKT signaling and decreased cell survival 
in a TRIB2-expressing leukemia model. The availability of target-validated compounds that act as 
rapid TRIB2 pseudokinase down-regulators via a direct effect on the pseudokinase represents a new 
way to evaluate TRIB2 physiology and cell signaling. It might also have a broader impact on the 
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rapidly developing pseudoenzyme field	 [46], where the concept of pseudokinase destabilization or 
elimination by targeted kinase ‘inhibitors’ [7] has a number of potentially useful applications.  
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RESULTS: 
Analysis of human TRIB2 using a thermal stability assay 
Human TRIB2 differs from TRIB1, TRIB3 and STK40 in the pseudokinase domain due to a Cys-rich 
region at the end of the b3 Lys-containing motif leading into the truncated aC-helix in the N-lobe 
(Fig. 1A, top).  We developed a differential scanning fluorimetry (DSF) assay [47-49] to examine 
thermal stability of full-length (1-343) His-tagged TRIB2 proteins, and compared it either to full-
length cAMP-dependent protein kinase (PKAc) catalytic subunit, which is a model for canonical 
kinases, or full-length C104Y TRIB2, in which Cys104 was replaced with the Tyr residue conserved in 
human TRIB1 and TRIB3 (Fig. 1A). Proteins were purified to homogeneity (Fig. 1A, bottom) and 
thermal stability based on unfolding profiles were determined for each protein (reported as a Tm value, 
Fig. 1B). As previously demonstrated	 [40], TRIB2 (Tm = ~39 °C) was much less thermostable than 
the canonical protein kinase (PKA, Tm = 46.3 °C). Remarkably, the C104Y single substitution 
induced stabilization of TRIB2, with the Tm value increasing to ~49 °C, comparable to that of human 
TRIB1	[15], suggesting an important structural role for this unique Cys residue in TRIB2 (un)folding 
dynamics. To confirm that recombinant TRIB2 binds to a known physiological target, we 
demonstrated that GST-tagged TRIB2 interacted preferentially with catalytically inactive (non Thr308-
phosphorylated) AKT1 in vitro (Fig. 1C). Consistent with a functional regulatory interaction between 
TRIB2 and AKT in cells [50], transient overexpression of TET-inducible FLAG-tagged TRIB2 in 
HeLa cells led to a large increase in endogenous AKT phosphorylation at the hydrophobic motif 
(Ser473, Fig. 1D), an established marker for AKT catalytic activity and generation of a downstream 
cellular anti-apoptotic signal	[51].  
A DSF screen for TRIB2-binding compounds using a kinase inhibitor library 
The ability of full-length recombinant human TRIB2 to bind to adenosine triphosphate (ATP) in the 
presence of EDTA	 [40, 48] confirms that a vestigial nucleotide-binding site is present within the 
pseudokinase domain. Moreover, our previous work established that an analogue-sensitive (F190G) 
TRIB2 variant could be stabilized by bulky pyrimidine analogues in vitro	[40].  To discover drug-like 
compounds for WT (full-length) TRIB2, we screened the Published Kinase Inhibitor Set (PKIS), a 
collection of high-quality class-annotated kinase inhibitors	[52]. We enforced cut off values of ~DTm 
= < -2 °C and > +3.5 °C (therefore eliminating ~97% of the library) to define ‘hit’ compounds that 
possessed the ability to destabilize or stabilize TRIB2 in a thermal stability assay (TSA) at a 1:4 
TRIB2:compound molar ratio (Fig. 1E and table S1). The top ‘stabilizing’ compound identified was 
GW693881A, a dual EGFR and HER2 thienopyrimdine inhibitor with a DTm of +4.7 °C. The top 
‘destabilizing’ compound was GW804482X, a thiophene polo-like kinase (PLK) inhibitor that 
induced a DTm of - 3.4 °C (Fig. 1E, red symbols). Most of the top stabilizing and destabilizing 
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compounds belonged to well-known ATP-competitive pyrimidine or quinazoline EGFR family 
chemotypes (fig. S1) [53-55], suggesting broad structural cross-reactivity between TRIB2 and a 
compound-binding EGFR and HER2 conformation. To build upon these findings, we screened a 
larger panel of known dual EGFR and HER2 inhibitors (fig. S2), and established that the clinical type 
I EGFR family inhibitors TAK-285 and lapatinib also stabilized TRIB2 in vitro (Fig. 1F). The ATP-
competitive covalent EGFR family inhibitors afatinib, neratinib and osimertinib (but not the unrelated 
covalent Bruton’s Tyrosine Kinase (BTK) inhibitor ibrutinib or the Type I EGFR-specific inhibitors 
erlotinib or gefitinib) destabilized TRIB2, similar to the PLK inhibitor GW804482X (Fig. 1F) and the 
dual EGFR family inhibitor GW569530A (fig. S1). As expected [15], purified TRIB1 (fig. S3A) was 
more thermostable than TRIB2 in the absence of kinase inhibitors (fig. S3B). However, it was not 
destabilised by afatinib, neratinib or osimertinib, although like TRIB2, destabilisation was evident in 
the presence of GW804482X (fig. S3C), in agreement with independent findings [56]. Compound 
effects were caused through pseudokinase targeting in the TSA, because no shift was elicited when 
the canonical kinase PKAc was compared in a side-by-side counter-screen, with dasatinib as a 
positive control (fig. S3D). The preclinical PLK inhibitors BI2536 and BI6727 (volasertib) had no 
discernible effects on TRIB2 stability in this assay, in contrast to the chemically distinct thiophene 
PLK inhibitor GW804482X (Fig. 1F).  
Afatinib, neratinib and osimertinib are covalent (type IV) inhibitors of EGFR family tyrosine kinases, 
interacting irreversibly with a conserved Cys residue in the canonical ATP-binding site	 [57]. The 
stabilization of TRIB2 by lapatinib, and the destabilization of TRIB2 by all three covalent  inhibitors, 
occurred in a dose-dependent manner (Fig. 1G and fig. S4). A C104Y TRIB2 mutant was no longer 
destabilized by either afatinib or neratinib, but remained ‘sensitive’ to lapatinib TAK-285 and 
GW804482X based on thermal-protection (Fig. 1H and fig. S5A). Importantly, none of these latter 
compounds contain the electrophilic ‘warhead’ required for covalent interactions (fig. S2). Elution 
profiles from Superdex 200 were identical for WT and C104Y TRIB2 (fig. S5B), confirming that both 
proteins were monomeric species in solution, with estimated Mr of 45.3 kDa. C104Y TRIB2 was also 
insensitive to thermal shift in the presence of ATP and EDTA (Fig. 1H and fig. S5C). These data 
suggest that the amino acid identity at TRIB2 position 104 is likely important both for ATP binding 
and interaction with covalent kinase inhibitors that induce TRIB2 destabilization in vitro.   
Mechanistic analysis of TRIB2 structural stability and TRIB2 compound binding 
Structural analysis of TRIB1 by X-ray crystallography and small angle X-ray scattering led to the 
proposal of an in cis self-assembly model, whereby the unique C-terminal tail region, which contains 
the conserved ‘DQLVP’ motif, binds directly to the pseudokinase domain adjacent to the short aC-
helix of TRIB1 [15, 16, 56]. To investigate whether this mechanism is also relevant in TRIB2, we 
generated a series of truncated proteins. These lacked either the N-terminal extension, which was 
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predicted to be disordered by both I-TASSER [58] and VSL2 [59], the C-terminal tail, or both N and 
C-terminal regions. We also generated a triple point mutant in which the ‘DQLVP’ tail motif, which 
is required for TRIB1 and TRIB2 cellular transformation in vivo [18], was mutated to a non-
functional ‘AQLAA’ sequence (Fig. 2A). Full-length (1-343) TRIB2, and TRIB2 lacking the N-
terminal domain (TRIB2 54-343), both exhibited similar Tm values of 39-40 °C (Fig. 2B). In contrast, 
deletion of the C-tail (TRIB2 1-318) changed TRIB2 stability, with Tm values falling to ~37°C, 
diagnostic of a destabilized TRIB2 conformation (Fig. 2B). Mutation of DQLVP to AQLAA further 
destabilized TRIB2, leading to a Tm value of ~36 °C (Fig. 2B). Using this panel of recombinant 
TRIB2 proteins, we measured the relative effects of kinase inhibitors on TRIB2 stability. Consistent 
with a lack of effect on compound interactions, deletion of the TRIB2 N-terminal region had no effect 
on DTm values induced by any compound. However, removal of the C-tail region (54-318 and 1-318 
mutants) abolished afatinib and neratinib-induced TRIB2 destabilization, but had a negligible effect 
on GW804482X binding (Fig. 2C). Consistently, destabilization by afatinib was also completely 
abolished in the AQLAA triple mutant, whereas neratinib effects were reduced by >50%. Notably, 
neither the destabilizing effect of GW804482X, nor the stabilizing effects of lapatinib or TAK-285 
differed between any of the TRIB2 proteins evaluated. These results suggest a very similar 
destabilizing mechanism induced by covalent EGFR family compounds via displacement of the 
TRIB2 C-tail, which is a unique feature of Tribbles pseudokinases [13, 15].  
To evaluate whether afatinib targeted unique Cys residues in the TRIB2 pseudokinase domain (Fig. 
1A), we performed mass spectrometry (MS) analysis to evaluate protein modification. As detailed in 
fig. S6A, incubation of TRIB2 with a 5-fold molar excess of afatinib led to covalent interaction with 
Cys 96 in TRIB2. A doubly charged chymotryptic product ion representing the TRIB2-derived 
DISC96Y:afatinib peptide adduct at m/z 543.2 (fig. S6A) and the isotopic ratios of the 35Cl or 37Cl-
containing peptide ions unequivocally confirmed Cys96 as a site of TRIB2 binding (fig. S6B). Having 
confirmed an intact mass for recombinant full-length TRIB2 of 43,587.09 Da, very similar to the 
predicted mass of 43,587.22 Da (fig. S6C), we were also able to ascertain that pre-incubation with 
afatinib generated covalent adducts containing predominantly either 1 or 2 molecules of afatinib. 
There was also some evidence for tri and tetra-modified TRIB2 adducts (fig. S6D). We next examined 
afatinib interaction with TRIB2 by Microscale Thermophoresis (MST), a biophysical technique for 
quantification of reversible biomolecular interactions [60]. This revealed an interaction between 
fluorescent NTA-coupled His-TRIB2 and two compounds, which could be fitted to reversible binding 
with Kd values of ~16 µM for afatinib and ~20 µM for TAK-285 (fig. S7, A and B). A sub-
micromolar interaction between MCL-1 and A1210477 served as a positive control [61]. In agreement 
with MS data (fig. S6), we therefore propose initial (reversible) binding of ATP-competitive afatinib 
[62, 63], prior to subsequent formation of a covalent adduct(s) with the TRIB2 pseudokinase domain. 
We also evaluated the potential interaction of afatinib and neratinib using TRIB2 modelled on the 
	 8 
C/EBP-bound ‘SLE-in’ conformation from TRIB1 [13, 56] and compared it to the known afatinib 
target EGFR (in a ‘DFG-in’ conformation) using AutoDock Vina [64]. Docking of covalent inhibitors 
revealed a putative binding pocket formed by residues from the vestigial TRIB2 C-helix, including 
Cys96, and the b3 strand (fig S8A). Afatnib and neratinib dock in a structurally similar pose in which 
the enamine beta carbon orients towards the sulfhydryl group of Cys96. This docking pose, however, is 
distinct from the afatinib-bound crystal structure of EGFR, wherein Cys797 is located in the D-helix. 
We performed molecular dynamics simulations (fig. S8B) on the docked complexes to assess the 
feasibility of the binding poses. Both afatinib and neratinib remained stably bound to TRIB2 for 
nearly 17 ns, suggesting that the binding poses are favorable and feasible. [65]. The enamine beta 
carbon remained within 3-5 Å of the Cys96 sulfur atom for the majority of the simulation. Given the 
rapid nature of the thiol-ene reaction coupled with the proximity of reactants, we believe that this time 
frame offers sufficient time for the formation of a covalent bond [66], which we confirmed by MS 
analysis. 
To validate the biochemical importance of Cys residues for afatinib binding, we next examined 
interaction with TRIB2 in which two Cys amino acids were mutated to non-thiol containing Ser 
residues. Individual or combined mutation of Cys96 and Cys104 to a Ser residue had no effect on the 
thermal stability (Tm) of the purified TRIB2 proteins (Fig. 2D), in contrast to the highly stabilizing 
effect of a Tyr at position 104 (Fig. 1B and fig. S5C). However, individual or joint mutation of 
Cys96and Cys104 to Ser severely blunted the destabilizing effect of afatinib and neratinib on TRIB2, in 
contrast to the non-covalent TRIB2 compound GW804482X or the EGFR family stabilizing 
compounds lapatinib and TAK-285 (Fig. 2E). Together, our findings confirm that these covalent 
compounds elicit effects on TRIB2 through Cys96 and/or Cys104. 
Evaluation of TRIB2 interactors in human cells 
To evaluate TRIB2 targeting by compounds in living cells, we generated a polyclonal TRIB2 
antibody and an isogenic stable HeLa cell line expressing TET-inducible FLAG-tagged human 
TRIB2. Polyclonal TRIB2 antibodies were equally efficient at recognising recombinant His-FLAG-
TRIB2 and cellular FLAG-TRIB2 as a commercial monoclonal FLAG antibody (fig. S9A). We also 
constructed a stable HeLa cell line expressing low levels of inducible FLAG-TRIB2 (fig. S9B). We 
estimated that ~1 ng of TRIB2 was expressed in 40 µg of whole cell lysate in the presence of TET, by 
comparing known amounts of recombinant His-FLAG-TRIB2 protein (fig. S9B).  
To quantify effects of TRIB2 expression on canonical signaling in model cells, we evaluated AKT 
phosphorylation. AKT became phosphorylated in stable HeLa cells after serum stimulation in the 
absence of TET (Fig. 3A). TRIB2 expression led to the appearance of a TRIB2 doublet 
(phosphorylation confirmed in the upper band by lambda phosphatase treatment, fig. S10), and a 
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marked increase in the extent and duration of AKT phosphorylation at Ser473. Using this HeLa cell 
model, we next evaluated the effects of small molecule inhibitors on TRIB2 signaling, by comparing a 
panel of in vitro TRIB2 destabilizing compounds discovered by DSF (afatinib, neratinib and 
osimertinib) with a series of control compounds. Brief (4 hours) exposure of TRIB2-expressing cells 
to afatinib led to a specific decrease in TRIB2 protein expression. All of the compounds evaluated 
were specific EGFR or EGFR family signaling pathway inhibitors, and consistently they all blocked 
ERK phosphorylation at these concentrations (Fig. 3B); any unique effects of drugs amongst this 
panel are therefore likely to be ‘off-target’ to EGFR and HER2. We next incubated cells for 
increasing lengths of time with afatinib. A rapid, time-dependent, elimination of TRIB2 protein was 
evident when cells were exposed to this drug, in contrast to DMSO controls in which TRIB2 protein 
remained relatively stable during the experiment (Fig. 3C), as expected	[19]. To evaluate intracellular 
interaction between TRIB2 and kinase inhibitors, we exposed HeLa cells expressing TET-inducible 
FLAG-TRIB2 to each compound, and quantified TRIB2 thermal stability in the cell extracts using a 
cellular TSA	(fig. S11)	[67]. Consistently, FLAG-TRIB2 was destabilized more rapidly than DMSO 
and erlotinib-treated controls in the presence of afatinib, becoming undetectable in extracts heated to 
45 °C (fig. S11). This was distinct from lapatinib, which partially stabilized TRIB2 in cell extracts, 
consistent with our in vitro analysis (Fig. 1F).  
Afatinib interacts with TRIB2 through a biochemical Cys-based mechanism, so we generated isogenic 
TET-inducible C96S or C96/104S TRIB2-mutant stable cell lines (fig. S12) and evaluated the effects 
of afatinib on exogenous TRIB2 stability. Afatinib (but not lapatinib or TAK-285) induced dose-
dependent loss of TRIB2 in WT-TRIB2 cells, which was partially prevented for C96S, and 
completely abolished in C96/104S TRIB2-expressing cells (quantified in Fig. 4A, right panels), 
demonstrating unequivocally that afatinib binds to TRIB2 in cells. Furthermore, afatinib (but not 
TAK-285 or erlotinib) treated WT-TRB2 cells exhibited a marked decrease in AKT Ser473 
phosphorylation, and this effect was abrogated in C96/104S TRIB2-expressing cells (Fig. 4B). 
Importantly, afatinib, TAK-285, and erlotinib all blocked ERK phosphorylation in WT and C96/104S-
TRIB2 isogenic cell lines, consistent with ‘on-target’ inhibition of their shared EGFR target (Fig. 4B).  
To investigate the mechanism of TRIB2 destabilization by afatinib, we added the drug to HeLa cells 
expressing WT-TRIB2 in the presence of the proteasome inhibitor MG132, which partially rescued 
TRIB2 degradation after both rapid and prolonged exposure to afatinib (Fig. 4C). This finding is 
consistent with previously reported proteasome-dependent TRIB2 turnover [68]. We further evaluated 
this mechanism using a range of MG132 concentrations and the clinical proteasome inhibitor 
bortezomib (Fig. 4D) [21]; under both conditions, afatinib-mediated destabilization of TRIB2 was 
decreased. This effect was in contrast to afatinib-induced TRIB2 destabilization, which was still 
observed in the presence of non-specific inhibitors of autophagy (AICAR) and lysosomal degradation 
(chloroquine) (Fig. 4D). Our observations are in line with published findings, which suggest that 
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TRIB2 fate is dependent upon turnover by the ubiquitin proteasome system (UPS) in human cancer 
cells	[19, 69]. However, the (non-covalent) TRIB1 and TRIB2-destabilizing compound GW804482X 
did not induce TRIB2 degradation in cells after a 4-hour incubation period, in contrast to proteasome-
dependent degradation induced by the same concentration of afatinib (fig. S13). 
High expression of TRIB2 drives AML in vivo by inhibiting myeloid differentiation and promoting 
proliferation [18, 35]. However, endogenous TRIB2 expression has been analysed previously only in 
a few cell types, in large part due to a lack of reliable TRIB2 reagents. Using our TRIB2 antibody, we 
evaluated endogenous expression of TRIB2 in the clinically-relevant U937 AML cell model (Fig. 
5A), and established that acute (4 hours) exposure to afatinib, but not lapatinib or erlotinib, decreased 
TRIB2 protein abundance in a dose-dependent manner (Fig. 5A). Consistent with their ability to 
inhibit EGFR signaling, all three compounds completely blocked ERK phosphorylation. We next 
established dose-dependent effects on both TRIB2 expression and AKT Ser473 phosphorylation in 
afatinib-treated U937 cells (Fig. 5B). Notably, these effects were tightly correlated with apoptotic 
induction of caspase 3 cleavage, but only at afatinib concentrations that also induced TRIB2 
degradation and concomitant loss of AKT Ser473 phosphorylation (Fig. 5B). To determine the impact 
of afatinib treatment on U937 cell viability, we quantified cellular cytotoxicity after 72 hours 
exposure (Fig. 5C). Afatinib (and neratinib) reduced cell viability with sub-micromolar IC50 values, 
whereas EGFR inhibitors erlotinib and gefitinib and the dual EGFR family inhibitor TAK-285 were 
comparably 10-20–fold less effective (Fig. 5C). Because these compounds do not induce cellular 
TRIB2 destabilization, AKT activation or caspase 3 activation, our data suggest that the TRIB2-
destabilizing compounds afatinib and neratinib possess an enhanced ability to kill AML-derived cells 
[50].  
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DISCUSSION: 
A drug-targetable regulatory mechanism for human TRIB2 
Cell Signaling can be controlled by non-enzymatic components, exemplified by mechanistically-
related families of pseudoenzymes such as pseudokinases [46]. In this study, we sought to target the 
cancer-associated pseudokinase TRIB2 with a chemical small molecule. To discover TRIB2-binding 
compounds, we exploited an unbiased TRIB2 thermal shift assay [40, 48], and identified multiple 
chemical classes of EGFR family member (typically EGFR and HER2, but never monovalent EGFR) 
kinase inhibitors. Several compounds induced stereotypical (positive) thermal shifts in TRIB2, 
consistent with binding in the atypical nucleotide-binding site	[48]. A second compound group led to 
marked TRIB2 (but not TRIB1) destabilization, and this could be explained through a Cys-directed 
covalent effect, in which the TRIB2 pseudokinase domain became uncoupled from its own C-tail by 
the compound. A similar mechanism has recently been proposed to explain thermally-distinct 
conformers in TRIB1, which shares ~70% identity with TRIB2 in the pseudokinase domain and C-tail 
[16]. Deletion of the TRIB1 C-tail also leads to destabilization of the TRIB1 pseudokinase domain 
[15], similar to the effects observed for TRIB2 described here. These data allow us to propose that 
TRIB2 pseudokinase-domain docking to the C-terminal tail is a dynamic interaction, which can be 
targeted with covalent ATP-competitive covalent inhibitors that induce a structural conformation 
associated with decreased stability in vitro.  
How do covalent EGFR family inhibitors target TRIB2? 
We focused our studies on electrophilic type IV kinase (covalent) inhibitors, since they are amenable 
to comparative chemical and mutational analysis in their targets [31, 70]. We confirmed that at-least 
two highly conserved TRIB2 Cys residues interact with afatinib [71] in vitro. These Cys-residues are 
unique within the distorted TRIB2 aC-helix (Fig. 1A). In most canonical kinases, including EGFR 
family members, helix positioning is critical for catalysis and switching between inactive and active 
enzyme conformations, both of which are targets for small molecules [72]. Dynamic helix positioning 
is also important for small molecule interactions, including ‘inactive’ conformations in kinases in 
which the aC-helix adapts upon binding, as described for HER2 [73]. The conformation of the 
flexible C-helix relative to the ATP binding P-loop can also create an allosteric binding pocket in 
canonical kinases such as ERK1/2, which can be targeted with selective non ATP-competitive 
inhibitors such as SCH772984 [74]. In TRIB2, the unique disposition of Cys residues (Fig. 1A) makes 
it vulnerable to destabilization by the covalent inhibitors afatinib, neratininb and osimertinib in vitro. 
These compounds also undergo a Michael addition to a distinct, but conserved, Cys residue in the 
ATP-binding site of EGFR-family tyrosine kinases (Cys797 in EGFR, Cys805 in HER2 and Cys803 in 
HER4) [61]. Afatinib also demonstrates low, but detectable, affinity for the pseudokinase domain of 
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HER3 [75, 76], which possesses a non-modifiable Ser residue (Ser794) at the equivalent position as 
Cys797 of EGFR, and assumes a pseudo ‘active’ catalytic conformation, despite possessing 
exceptionally low kinase activity [76, 77]. At nanomolar concentrations, afatinib is relatively specific 
for EGFR and HER2 in cells, although at micromolar concentrations other canonical kinases also 
appear to be targeted [9]. Moreover, osimertinib possesses cross-reactivity with kinases [9] and non-
kinases such as lysosomal cathepsins [78]. In the absence of a high-resolution TRIB2 pseudokinase 
structure, we can only model the conformation(s) relevant for small molecule interaction, although the 
N-lobe has shared (SLE motif) and distinct (Cys96 and Cys104) features compared to TRIB1, TRIB3 
and STK40 [15], and TRIB1 adopts at least two conformations, one of which (‘SLE-in’) appears 
vulnerable to small molecules [56]. This is confirmed by biochemical differences in the ability of 
TRIB2 to bind weakly to ATP, which likely predisposes it to C-helix targeting by the kinase inhibitors 
identified here (fig. S8). None of the EGFR family members possess a Cys residue in the C-helical 
region conserved in TRIB2, and the overall identity between HER2 and TRIB2 in the (pseudo)kinase 
domain is very low indeed (~22%). We believe that our discovery of TRIB2 binding to covalent 
compounds like afatinib owes as much to the availability of reactive Cys residues adjacent to the 
unique allosteric pocket in the pseudokinase domain, as to their weak affinity for the vestigial ATP-
binding site. Our work also builds on previous studies in which pseudokinase domains were targeted 
with compounds [3], such as TX1-85-1 [8], which covalently binds Cys721 in the roof of the ATP site 
(inducing HER3 degradation in cells) and non-covalent JAK2 JH2 (pseudokinase) domain ligands 
[79, 80]. 
In the course of compound screening, we discovered that unrelated classes of ATP-competitive kinase 
inhibitors, including thienopyrimidines [55] and thiazolylquinazolines [53] also bound to TRIB2 in 
vitro. In contrast to destabilization (a feature of covalent TRIB2-binding compounds) these 
compounds stabilize TRIB2, similar to lapatinib and the pyrrolo[3,2-d]pyrimidine EGFR-family 
inhibitor TAK-285, which are known to bind to HER2 in an active-like conformation [81]. Of 
relevance, lapatinib and TAK-285 did not induce TRIB2 degradation in cells, although CETSA 
suggested an interaction with lapatinib (fig. S11). Previous studies found that lapatinib can also 
deprive HER2 of an interaction with the Hsp90-Cdc37 system, leading to time-dependent HER2 
degradation at micromolar concentrations [82]. Our data prove that the cellular mechanism by which 
TRIB2 stability is regulated by compounds is proteasome-based, and we speculate that an afatinib-
induced conformational change might induce TRIB2 ubiquitination, or negatively regulate interaction 
with an unknown stabilizing factor(s), similar to effects of Hsp90 inhibitors on Cdc37 kinome clients	
[83-85]. Consistently, TRIB2 abundance is regulated by ubiquitination [19, 68, 69], and future work 
will attempt to correlate TRIB2 small molecule interactions with dynamic changes in ubiqutination 
status.  
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The future: Targeting TRIB2 with kinase inhibitors in cancer cells and beyondThe finding that 
TRIB2 stabilizing and destabilizing small molecule compounds can be discovered by DSF profiling is 
an important advance for the analysis of compounds that target catalytically-deficient pseudokinases, 
and confirms that TRIB2 represents a bona fide pseudokinase drug target [5]. We found that 
conserved Cys residues in TRIB2 make it vulnerable to families of small molecule kinase inhibitors 
originally developed as dual nanomolar covalent EGFR and HER2 inhibitors. These residues also 
represent an additional form of selectivity filter, permitting targeting of TRIB2 by these compounds at 
micromolar concentrations in cells. Based on this mechanism, a lack of equivalent Cys residues in 
other pseudokinases, including TRIB1, TRIB3 and STK40, likely precludes interaction with covalent 
compounds such as afatinib through this mechanism.  
Using a chemical genetic approach, we provide evidence that afatinib induces on-target effects 
through TRIB2 stability and AKT signaling in a variety of human cancer cells. Experimental ‘on-
target’ effects of covalent TRIB2-destablising agents were confirmed using chemical genetics and a 
mutant TRIB2 allele, similar to ‘drug-resistance’ approaches developed for compound target 
validation in the kinase inhibitor field	[86-89]. Importantly, drug effects were prevented by mutation 
of two TRIB2 Cys C-helix residues, confirming a meaningful cellular interaction.  Afatinib binding 
was also validated by DSF, MS, MST and by employing in-cell TSA (CETSA) approaches with 
exogenous TRIB2. Finally, we established that afatinib (and neratinib) exhibit sub-micromolar 
toxicity in the human AML model cell line U937, where they are 10-20 fold more effective at cell 
killing compared to equipotent EGFR-family or EGFR specific inhibitors [72], which do not degrade 
TRIB2 but still block ERK activation. U937 cells are known to be hypersensitive to TRIB2 siRNA 
knock-down	and to require TRIB2 for cell survival [68]. 
Conclusions 
Our work demonstrates that covalent inhibitors such as afatinib possess TRIB2 degrading-activity in 
human cells at micromolar concentrations, in similar ranges to those reported for other destabilizing 
kinase inhibitors, such as the related TRIB2 destabilizing quinazaline neratinib [90]. Although we 
cannot rule out simultaneous dual effects of afatinib on TRIB2 and ERK/AKT pathways contributing 
to cellular phenotypes, we provide direct evidence that TRIB2-binding is required for TRIB2 
destabilization and AKT regulation. Should an appropriate concentration of drug permit a direct 
TRIB2 interaction, an ‘off-target’ TRIB2-dependent phenotype might be relevant to compound 
efficacy (or side-effects) in patient groups exposed to high concentrations of these covalent 
compounds. Many severe side effects of drugs are only detected after long-term clinical use, 
potentially leading to their withdrawal [91], and covalent drugs have the potential to accumulate to 
relatively high concentrations in cells.  Indeed, side-effects of lapatinib [92] and afatinib [93] are 
already well-established in patients. Based on our mechanistic studies, it will be interesting to develop 
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ELISA-based procedures to quantify effects of these drugs on TRIB2 protein stability in clinical 
samples obtained from patients, as part of broader proteomics approaches to establish all the 
intracellular targets of such compounds. Our study also provides impetus for generating improved 
(ideally TRIB2-specific) covalent compounds that induce TRIB2 degradation at lower (nanomolar) 
concentrations, ideally by synthesising compounds in which the effects of eliminating or preserving 
tyrosine kinase inhibition can be compared side-by-side. In the latter case, simultaneous elimination 
of TRIB2 and inhibition of the ERK-signaling pathway could be a polypharmacological asset, 
especially if TRIB2-dependent drug-resistance in tumor cells [39, 50] can be modulated by tyrosine 
kinase inhibition. Together, our data establish a new paradigm for the pharmacological evaluation of 
agents that interfere with TRIB2-based signaling and raises the intriguing possibility that clinical 
inhibitors might be used as TRIB2-degrading agents in research, and possibly clinical, contexts. This 
information can also be exploited in the future for targeting a variety of TRIB2-overexpressing solid 
[94, 95] and haematological [21, 68] tumors. 
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MATERIALS AND METHODS: 
Chemicals, reagents, antibodies and TRIB2 small molecule screen 
Tetracycline (TET) and doxycycline, MG132, AICAR and chloroquine were purchased from Sigma. 
Afatinib, neratinib, osimertinib, ibrutinib, erlotinib, lapatinib, TAK-285, BI2536, BI6727, gefitinib 
and bortezomib were purchased from LC laboratories or Selleck. Total AKT, pSer 473 AKT, pThr 
308 AKT, total ERK1/2, dual pThr 202/pTyr 204 ERK1/2, cleaved Caspase 3 and a-tubulin 
antibodies were purchased from New England Biolabs and employed as previously described [51, 96]. 
6His-HRP and α-FLAG antibodies were purchased from Sigma, GAPDH antibody was purchased 
from Proteintech and a polyclonal rabbit α-TRIB2 antibody was raised towards a unique N-terminal 
human TRIB2 sequence and affinity purified prior to evaluation with recombinant TRIB2 and a 
variety of human cellular extracts.  
The PKIS chemical library (designated as SB, GSK or GW compounds) comprises 367 ATP-
competitive kinase inhibitors, covering ~30 chemotypes (~70% with molecular mass <500 Da and 
clogP values <5) that were originally designated as ATP-competitive inhibitors of 24 distinct protein 
kinase targets, including multiple EGFR and HER2 tyrosine kinase classes [52]. Compounds were 
stored frozen as 10 mM stocks in DMSO. For initial screening, compounds were pre-incubated with 
TRIB2 for 10 minutes and then employed for DSF, which was initiated by the addition of fluorescent 
SYPRO Orange. For dose-dependent thermal-shift assays a compound range was prepared by serial 
dilution in DMSO, and added directly into the assay to the appropriate final concentration, as 
previously described [97] [Add Byrne BJ papers]. All control experiments contained 2% (v/v) DMSO, 
which had essentially no effect on TRIB2 stability.   
Cloning, Site Directed Mutagenesis and recombinant protein production  
pET30 6His-TRIB2 (and various deletion or amino acid substitution constructs, including an N-
terminal FLAG-tagged TRIB2, termed His-FLAG-TRIB2), and pET30a 6His-PKAc, which encodes 
catalytically-active cAMP-dependent protein kinase domain, have been described previously [40, 49]. 
Full length TRIB2 was also cloned into pOPINJ to generate a His-GST-TRIB2 encoding construct for 
Glutathione-S-transferase (GST) pull-down assays. MCL-1 and A-1210477 were prepared as 
described [61]. TRIB1 (84-372) was a kind gift from Dr. Peter Mace, and was purified as described 
previously for TRIB2 [40]. Briefly, protein expression was induced in BL21(DE3) pLysS bacteria 
with 0.4 mM IPTG, and after overnight culture at 18°C, proteins were purified to near homogeneity 
using an initial affinity step (immobilised metal affinity chromatography (IMAC) or glutathione-
sepharose chromatography) followed by size exclusion chromatography (16/600 Superdex 200) in 
appropriate buffers. S473D 6His-AKT1 (DU1850, amino acids 118-470), either active (PDK1-
phosphorylated to a specific activity of 489 U/mg) or inactive, were purchased from the DSTT 
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(University of Dundee), and stored at -80°C prior to analysis. Site directed mutagenesis was 
performed as previously described [98], using KOD Hot Start DNA polymerase (Millipore) and 
appropriate mutagenic primer pairs (sourced from IDT). All plasmids were Sanger-sequenced across 
the entire coding regions to confirm expected codon usage. 
Differential Scanning Fluorimetry (DSF) 
Thermal-shift assays were performed using an Applied Biosystems StepOnePlus Real-Time PCR 
instrument using a standard DSF procedure previously developed and validated for the analysis of 
kinases [47, 49] and pseudokinases [48]. All proteins were diluted in 20 mM Tris/HCl (pH 7.4), 100 
mM NaCl and 1 mM DTT to a concentration of 5 µM and then incubated with the indicated 
concentration of compound in a total reaction volume of 25 µL, with final concentration of 2% (v/v) 
DMSO. SYPRO Orange (Invitrogen) was used as a fluoresecence probe. The temperature was raised 
in regular 0.3 °C intervals from 25°C to 95°C. Compound binding experiments were assessed in 
duplicate and then reported relative to DMSO controls. 
Mass Spectrometry analysis of TRIB2 afatinib binding 
To evaluate TRIB2 binding in vitro, afatinib was incubated for 15 min with purified 6His-TRIB2 at a 
1:10 molar ratio, then denatured with 0.05 % (w/v) RapiGest SF (Waters, UK) and digested with 
chymotrypsin (1:20 protease:protein (w/w) ratio) for 16 h at 25 °C. RapiGest hydrolysis was induced 
by the addition of triflouroacetic acid (TFA) to 1 % (v/v), incubated at 37 °C for 1h. Insoluble product 
was removed by centrifugation (13, 000 x g, 20 min).  Reversed-phase HPLC separation was 
performed using an UltiMate 3000 nano system (Dionex) coupled in-line with a Thermo Orbitrap 
Fusion Tribrid mass spectrometer (Thermo Scientific, Bremen, Germany). 500 fmol digested peptides 
were loaded onto the trapping column (PepMap100, C18, 300 µm × 5 mm), using partial loop 
injection, for 7 min at a flow rate of 9 µL/min with 2% (v/v) MeCN, 0.1% (v/v) TFA and then 
resolved on an analytical column (Easy-Spray C18 75 µm × 500 mm, 2 µm bead diameter column) 
using a gradient of 96.2% A (0.1% (v/v) formic acid (FA)): 3.8% B (80% (v/v) MeCN, 0.1% (v/v) 
FA) to 50% B over 35 min at a flow rate of 300 nL/min. MS1 spectra were acquired over m/z 400 – 
1500 in the orbitrap (60 K resolution at 200 m/z). Data-dependent MS2 analysis was performed using 
a top speed approach (cycle time of 3 s), using higher-energy collisional dissociation (HCD) and 
electron-transfer and higher-energy collision dissociation (EThcD) for fragmentation, with product 
ions being detected in the ion trap (rapid mode). Data were processed using Thermo Proteome 
Discoverer (v. 1.4) and spectra were searched in MASCOT against the E. coli IPI database with the 
added sequence of full-length 6His-TRIB2 (1-343). Parameters were set as follows: MS1 tolerance of 
10 ppm, MS/MS mass tolerance of 0.6 Da, oxidation of methionine and afatanib binding at cysteine as 
variable modifications. MS2 spectra were interrogated manually.  
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To evaluate the interaction between afatinib and intact TRIB2 protein, TRIB2 was incubated with 
afatinib as above, and then desalted using a C4 desalting trap (Waters MassPREP™ Micro desalting 
column, 2.1 × 5 mm, 20 µ m particle size, 1000 Å pore size). TRIB2 was eluted with 50 % (v/v) 
MeCN, 0.1 % (v/v) formic acid. Intact TRIB2 mass analysis was performed using a Waters nano 
ACQUITY Ultra Performance liquid chromatography (UPLC) system coupled to a Waters SYNAPT 
G2. Samples were eluted from a C4 trap column at a flow rate of 10 µL/min using three repeated 0-
100 % acetonitrile gradients. Data was collected between 400 and 3500 m/z and processed using 
MaxEnt1 (maximum entropy software, Waters Corporation).  
 
TRIB2 modeling and compound docking 
The structure model of human TRIB2 pseudokinase domain [13]  (UniProt ID: Q92519) (residues 58-
308) was built with MODELLER [99] using a crystal structure of TRIB1 pseudokinase in the open 
‘SLE-in’ conformation [56] as a template. The homology model was subjected to energy 
minimization using the Rosetta Relax protocol [100]. The chemical structures of afatinib (CID 
10184653) and neratinib (CID 9915743) were retrieved from PubChem. Afatanib and neratinib were 
docked to our TRIB2 model using AutoDock Vina [62] with an exhaustiveness of 100, rigid body, 
and a search space centered on Cys96. Top poses were identified where the enamide group localizes 
near the Cys96 sulfhydryl moiety. For comparison, we employed a crystal structure of EGFR in 
complex with afatinib (PDB: 4g5j). Missing disordered loop regions in the structure were modelled 
using RosettaRemodel [101] with default settings. The covalently-bound afatinib was removed from 
the structure and allowed to re-dock with AutoDock Vina using the same parameters from TRIB2, 
with the exception of search space being centered on EGFR Cys797. Top poses were identified where 
the enamide group localized near the Cys797 sulfhydryl moeity. For molecular dynamics simulations, 
TRIB2 and EGFR binding modes were parameterized with GROMACS 5.1.3. Afatinib and neratinib 
were parameterized with GAFF [102] using ACPYPE [103].  Protein was fixed with AMBER99SB-
ILDN force field and solvated with TIP3P water model in a dodecahedron box at least 1 nm larger 
than the protein in all directions. Sodium and chloride ions were added to neutralize the system. 
Neighbor lists for non-bonded interactions were maintained by the Verlet cutoff scheme and long-
range electrostatics were calculated by the Particle Mesh Ewald method. Energy minimization was 
performed with steepest descent followed by conjugate gradient until the total energy was under 100 
kJ/mol/nm. The system was heated from 0 to 310 K, then pressurized to 1 bar. Position restraint was 
applied to non-hydrogen atoms during equilibration. The production run was performed in 2 fs time-
steps. Data visualization was performed in VMD and PyMOL. 
 
MicroScale Thermophoresis  
A Monolith NT.115 instrument (NanoTemper Technologies GmbH) was employed for MST analysis. 
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His-TRIB2 was initially labelled with a NanoTemper labelling kit; the fluorescent red dye NT-647 
was coupled via NHS chemistry to the N-terminal His-tag, placing the fluorophore away from the 
pseudokinase domain. For MST, the reaction was performed in 20 mM Bicine pH 9.0, 100 mM NaCl, 
5% glycerol, 0.05% Tween-20 and 2 % (v/v) DMSO. Fluorescent TRIB2 (~5 µM) was kept constant 
in the assay, while final afatinib and TAK-285 concentration was titrated over a 3 nM and 50-100 µM 
range. Near-saturation binding was achieved, allowing for an affinity to be estimated for the 
reversible interaction between afatinib, TAK-285 and fluorescent TRIB2. NT-647-linked MCL-1 and 
A-1210477 was employed as a positive control. 
Cell lines and reagents 
Flp-In T-REx parental HeLa cells (Invitrogen) were cultured in DMEM with 4 mM L-glutamine, 10 
% (v/v) Foetal Bovine Serum (FBS), Penicillin and Streptomycin (Gibco) as described [86]. To 
engineer Tetracycline (TET)-controlled expression of FLAG-tagged full length TRIB2 in human Flp-
In T-REx cell lines, the host plasmid pcDNA5/FRT/TO, encoding full length TRIB2 sequences (or 
appropriate amino acid substitution(s)), with a single N-terminal FLAG tag (1 µg DNA per well in a 6 
well plate of cells) were co-transfected with 9 µg of pOG44 Flp-Recombinase Expression Vector 
using lipofectamine. Cells that had successfully integrated the FLAG-tagged TRIB2 sequence were 
stably selected with 200 µg/mL Hygromycin B, according to the manufacturer’s instructions. TET 
was added at a final concentration of 1 µg/ml to medium in order to induce FLAG-TRIB2 expression. 
For transient transfection, 50% confluent HeLa cells were transfected with 40 µg DNA per 10 cm dish 
for 48 h prior to lysis.  
For serum starvation, stable HeLa cells were grown until ~60% confluent in complete medium 
(+FBS), washed with PBS, and replaced with serum-free DMEM for 16 h. Cells were then incubated 
with DMEM containing 10% (v/v) FBS ± 1 µg/ml TET for 16 h, followed by addition of appropriate 
inhibitor for 4h. All whole cell lysates were generated with modified RIPA buffer (see below). Non-
adherent AML-derived human U937 cells (which express high levels of endogenous TRIB2 protein) 
were supplied by Dr Karen Keeshan, University of Glasgow and were cultured as previously 
described [21].    
MTT cytotoxicity assay 
U937 cells were seeded in a 96 well plate at a concentration of 0.2 x 106 cells/mL, 18 hours prior to 
compound addition, which was performed in triplicate, with all experiments including a final 
concentration of 0.1% DMSO (v/v). To quantify U937 cell viability, metabolic activity was assessed 
72 h after compound exposure using an MTT assay (Abcam), as described previously [104]. Briefly, 
Thiazolyl blue tetrazolium bromide was dissolved in PBS and added to cells at a final concentration 
of 0.25 mg/mL and incubated at 37 °C for 3 hours. The reaction was stopped by the addition of 50 µL 
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of acidified 10% SDS, followed by reading of absorbance at 570 nm. Viability was defined relative to 
DMSO-containing controls incubated for the same period of time. 
Immunoblotting and CETSA 
HeLa and U937 whole cell lysates were generated using a modified RIPA buffer (50 mM Tris–HCl 
pH 7.4, 1 % (v/v) NP-40, 1 % (v/v) SDS, 100 mM NaCl, 100 nM Okadaic acid) supplemented with 
protease and phosphatase inhibitors (Roche), and brief sonication. For western blotting, samples were 
boiled for 5 min in sample buffer (50 mM Tris pH 6.8, 1% SDS, 10% glycerol, 0.01% Bromophenol 
Blue, 10 mM DTT). Subsequently, and between 40 and 120 µg of total protein was resolved by SDS–
PAGE followed by transfer onto nitrocellulose membrane (BioRad). After blocking in pH TBS-T + 
5% milk, pH 7.4), primary and secondary antibodies were incubated in the same condition, and 
proteins were detected using HRP-conjugated antibodies and ECL reagent. Immunoblots were 
quantified using ImageJ software, as previously described	[96]. For lambda phosphatase treatment, 40 
µg FLAG-TRIB2 expressing stable cell extracts in lysis buffer without SDS and phosphatase 
inhibitors were incubated with 10 ng of purified l-phosphatase for 30 min at 37°C prior to processing 
for western blotting. 
For in-cell CETSA we employed a previously published procedure [105]. Briefly, stable HeLa cells 
were incubated with TET for 16h to induce expression of FLAG-TRIB2, and at ~90% confluency, 
were incubated with 0.1% (v/v) DMSO or 100 µM of the indicated compound for 1h. Intact cells were 
isolated by trypsinization (1 min) and resuspended in PBS, and then aliquoted into individual PCR 
tubes prior to heating at the indicated temperature in a PCR thermal cycler for 3 min. Cells were then 
placed on ice for 2 min and lysed by sonication, prior to centrifugation at 16,000 x g for 20 minutes at 
4°C. The soluble lysate was analysed for the presence of FLAG-TRIB2 and a-tubulin by 
immunoblotting. 
Statistical analysis 
All experimental procedures were repeated in at least 3 separate experiments with matched positive 
and negative controls (unless stated otherwise). Results are expressed as mean ± SD for all in vitro 
experiments and data are expressed as the mean ± standard deviation. When applied, statistical 
significance of differences (*P ≤0.05) was assessed using a Students t-test for normally-distributed 
data. All statistical tests were performed using Prism 7 (GraphPad Software) 
SUPPLEMENTARY MATERIALS: 
Fig. S1. Discovery of multiple PKIS compounds as TRIB2-binding compounds. 
Fig. S2. Chemical structure of pre-clinical and clinical compounds evaluated in this study. 
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Fig. S3. Validation of DSF assay using TRIB1 and a PKAc counter-screen.  
Fig. S4. Thermal melting profiles of TRIB2 using DSF. 
Fig. S5. Analysis of C104Y mutation in TRIB2. 
Fig. S6. MS-based analysis of the covalent TRIB2:afatinib complex. 
Fig. S7. Microscale Thermophoresis (MST) assay. 
Fig. S8. Molecular docking analysis. 
Fig. S9. A new TRIB2 antibody for quantitative analysis of TRIB2 expression levels and 
stability. 
Fig. S10. Analysis of TRIB2 dephosphorylation in cell extracts. 
Fig. S11. TRIB2-binding to afatinib induces destabilization relative to DMSO in a whole cell 
thermal shift assay (CETSA). 
Fig. S12. Comparative protein expression analysis of stable HeLa FLAG-TRIB2 cell lines. 
Fig. S13. Lack of effect of the non-covalent TRIB1 and TRIB2 destabilizing compound 
GW804482X on TRIB2 stability in TRIB2-expressing HeLa cells. 
Table S1. PKIS compound screening data for full-length TRIB2 
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FIGURE LEGENDS: 
Fig. 1. Full-length TRIB2 is a target for protein kinase inhibitors in vitro 
(A) Top, sequence alignment of human TRIB2, TRIB1, TRIB3, and STK40/SgK495, highlighting 
Cys-rich residues (numbered in red) in the TRIB2 pseudokinase domain. Bottom, blot of the 
recombinant proteins employed for in vitro analysis. 5 µg of the indicated purified proteins were 
resolved by SDS-PAGE. WT, wild-type. (B) Thermal denaturation profiles of recombinant proteins. 
A representative unfolding profile is shown.  Tm values (±SD) were obtained from 3 separate 
fluorescence profiling experiments, each point assayed in duplicate. (C) The ability of GST-TRIB2 to 
interact with active (PDK1-phosphorylated) or inactive (non PDK1-phosphorylated) S473D AKT1 
was assessed by GSH-sepharose pull-down followed by immunoblotting. PDK1 phosphorylated 
S473D AKT is phosphorylated on Thr308 (right panel), but binds much more weakly to TRIB2. 
‘Master-mix’ input is shown,left. (D) Transient transfection of TET-inducible FLAG-TRIB2 leads to 
increased AKT phosphorylation on Ser473. (E) TRIB2 DSF screen using PKIS. 5 µM His-TRIB2 was 
used for all DSF analysis. ΔTm values were calculated for each compound (N=2). Scattergraph of data 
highlights a wide variety of compounds that either stabilize or destabilize TRIB2 in vitro. Cut off 
values of > + 3.5 °C and < - 2°C were used to designate ‘hits’. (F) Comparative DSF analysis of 
clinical and preclinical kinase inhibitors as potential TRIB2-binding compounds. LAP=lapatinib, 
TAK=TAK-285, AFA=afatinib, NER=neratinib, OSI=osimertinib, IBR=ibrutinib, ERL=erlotinib, 
GEF=gefitinib. (G) Dose-dependent analysis of thermal shifts induced by clinical TRIB2-binding 
compounds. Compounds were tested at 5, 10, 20, 40, 80 and 160 µM. (H) Profiling of TRIB2 and 
C104Y with selected inhibitors by DSF.  
Fig. 2. TRIB2 thermal stability is modulated through Cys binding to covalent inhibitors  
(A) Top, schematic cartoon of TRIB2 with domain boundaries numbered and cysteine residues 
highlighted (red). (Bottom) SDS-PAGE of 5 µg recombinant TRIB2 proteins. (B) Thermal 
denaturation profiles of 5 µM WT-TRIB2 (amino acids 1-343), three truncated variants and an 
AQLAA triple-point mutant. Representative curves for each protein and average Tm values (±SD) are 
shown, calculated from N=3 experiments. (C) Thermal shift analysis of TRIB2 deletion and AQLAA 
proteins measured in the presence of a panel of compounds (20 µM). The change in Tm value (DTm) is 
reported from N=3 experiments, each performed in triplicate, and the chemical structures of each 
compound are shown for comparison. AFA=afatinib, NER=neratinib, LAP= lapatinib, ERL=erlotinib. 
(D) Thermal denaturation profiles for purified TRIB2 and C96S, C104S and C96/104S proteins. (E) 
Thermal shift analysis of TRIB2 Cys-mutated proteins measured in the presence of a panel of 
compounds (20 µM). The change in Tm value (DTm) is reported from N=3 experiments.  
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Fig. 3: Afatinib promotes rapid degradation of FLAG-TRIB2 in an inducible HeLa model 
(A) Uninduced (-TET) or Tetracycline-induced (+TET) HeLa cells containing a stably integrated 
FLAG-TRIB2 transgene were serum starved for 16 hours prior to the addition of serum and lysed at 
the indicated times. Whole cell extracts were blotted with FLAG antibody to detect FLAG-TRIB2, 
pSer 473 AKT. Total AKT and total GAPDH served as loading controls. (B) A selection of clinically 
approved kinase inhibitors, including dual EGFR and HER2 and EGFR-specific compounds, were 
added to TET-induced cells at a final concentration of 10 µM. Stable cells were induced to express 
FLAG-tagged TRIB2 with tetracycline for 16 hours prior to inhibitor treatment for 4 hours. 
AFA=afatinib, NER=neratinib, OSI=osimertinib, IBR=ibrutinib, LAP=lapatinib, ERL=erlotinib, 
GEF=gefitinib. Whole cell extracts were immunoblotted with FLAG, phosphorylated ERK (pERK 
1/2), total ERK or GAPDH antibodies. (C) Stable HeLa cells were incubated with TET for 16 hours, 
and then incubated with DMSO (top panels) or 10 µM afatinib (AFA, bottom panels) prior to lysis at 
the indicated time. 1-hour and 16-hour samples were pre-treated with lambda protein-phosphatase 
(lPP) prior to SDS-PAGE. Whole cell extracts were immunoblotted with FLAG or GAPDH 
antibodies.  Blots are representative of 3 independent experiments. 
Fig. 4. ‘On-target’ degradation of TRIB2 by afatinib: C96/104S TRIB2 double point mutant is 
resistant to degradation  
(A) The indicated concentration of afatinib, lapatinib or TAK-285 was incubated for 4 hours with 
isogenic stable HeLa cells expressing FLAG-tagged WT-TRIB2, C96S or C96/104S TRIB2 (induced 
by TET exposure for 16 hours). After lysis, whole cell extracts were immunblotted with the indicated 
antibodies. Right, FLAG-TRIB2 abundance was quantified after exposure to 10, 15 and 20 µM 
afatinib relative to DMSO controls using ImageJ densitometry software. Data are means ± S.D. from 
N=3 independent biological replicates. (B) WT and C96/104S stable HeLa cell lines were subjected to 
serum block-and-release protocol in the presence (+TET) or absence (-TET) of tetracycline. 
Subsequently, the indicated compounds (10 µM) were added for 4 hours prior to cell lysis and 
immunoblotting with the indicated antibodies. AFA=afatinib, ERL=erlotinib. (C) FLAG-tagged 
TRIB2 expressing HeLa cells were incubated with (0.1% v/v) DMSO or afatinib (10 µM), in the 
presence or absence of MG132 (10 µM for 4 hours, left) or at the indicated time points (right) prior to 
lysis and processing for immunoblotting. (D) Left, FLAG-TRIB2 expressing stable cells were 
incubated with the indicated concentration of MG132 in the presence or absence of 10 µM afatinib 
(AFA) for 4 hours prior to cell lysis and immunoblotting. Right, FLAG-TRIB2 expressing stable cells 
were incubated for 1 hour with MG132 (10 µM), bortezomib (BOR; 10 µM), AICAR (AIC; 1 mM) or 
Chloroquine (CLQ; 50 µM) prior to the addition of AFA (10 µM) for an additional 4 hours followed 
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by lysis and immunoblotting with the indicated antibodies. Blots are representative of 3 independent 
experiments. 
Fig. 5. Afatinib rapidly destabilizes endogenous TRIB2 and specifically induces caspase-3 
cleavage and U937 cytotoxicity 
(A) Endogenous TRIB2 is destabilized in human U937 cells in a dose-dependent manner after a 4-
hour exposure to AFA. Cells were incubated with either 0.1% (v/v) DMSO, the indicated 
concentrations of afatinib, or lapatinib (LAP; 10 µM), erlotinib (ERL; 10 µM) or of the proteasome 
inhibitor bortezomib (BOR; 10 µM) for 4 hours prior to lysis and immunoblotting of endogenous 
TRIB2, pERK or cleaved caspase 3. GAPDH served as a loading control. (B) Endogenous TRIB2 is 
destabilized after exposure to afatinib for 24 hours, concomitant with reduced AKT phosphorylation 
at Ser473. After cell collection and lysis, whole cell extracts were immunoblotted with the indicated 
antibodies. AKT and GAPDH served as loading controls; ERL and BOR were used at 10 µM. (C) The 
cytotoxicity of a panel of TRIB2-destabilsing small molecules (afatinib, AFA; neratinib, NER) were 
compared to EGFR inhibitors or the TRIB2 stabilizer TAK-285 (TAK). MTT assays were performed 
after 72 hours’ compound exposure, with bortezomib (BOR) used as a positive control. IC50 values 
(nM, mean ± SD) are derived from N=3 independent experiments, each performed in triplicate. 
Statistical analysis confirmed a significant difference in cytotoxicity between AFA and ERL (students 
t-test p value = 0.0104) BOR and ERL (p value = 0.0072) and NER and ERL (p value = 0.0104). 
Blots are representative of 3 independent experiments. 
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